title: An increase in plasma cholesterol independent of thyroid function during long-term amiodarone therapy. A dose-dependent relationship.
abstract: OBJECTIVE
  To determine whether long-term amiodarone treatment is associated with a rise in plasma cholesterol, and, if so, to analyze its relation with thyroid function.
  
  
  METHODS
  Consecutive entry trial, including cardiac patients who initiated amiodarone medication but excluding those with abnormal thyroid function (defined as peak thyroid-stimulating hormone [TSH] response to thyrotropin-releasing hormone [TRH] less than 2.8 or greater than 22.0 mU/L) either before or during amiodarone treatment.
  
  
  METHODS
  Twenty-three patients who remained euthyroid were studied.
  
  
  METHODS
  Oral administration of amiodarone (mean duration of treatment, 17 months; range, 6 to 30 months).
  
  
  METHODS
  Fasting plasma lipids, thyroid hormones, and peak TSH to TRH values were recorded before and every 6 months during amiodarone treatment.
  
  
  RESULTS
  Plasma cholesterol gradually increased from 5.1 +/- 0.2 mmol/L before treatment to 6.9 +/- 0.8 mmol/L after 30 months of amiodarone medication (P less than 0.001); the peak TSH response to TRH did not change. When age- and sex-specific reference values were applied, 30% of the patients had cholesterol values above the 75th percentile before treatment; this number rose to 69% after 2 years of treatment. The rise in plasma cholesterol was associated with an equal increase in apoprotein B. Plasma cholesterol was not related to the daily dose of amiodarone or to plasma concentrations of amiodarone, desethylamiodarone, thyroxine (T4), triiodothyronine (T3), or reverse triiodothyronine (rT3). Linear regression analysis indicated a positive relation between plasma cholesterol and the cumulative dose of amiodarone (r = 0.25, P less than 0.05).
  
  
  CONCLUSIONS
  Long-term amiodarone treatment is associated with a dose-dependent increase in plasma cholesterol that is independent of thyroid function.
authors.affiliation: University of Amsterdam Academic Medical Center, The Netherlands.
authors.forename: W M
authors.initials: WM
authors.lastname: Wiersinga
authors.forename: M D
authors.initials: MD
authors.lastname: Trip
authors.forename: M H
authors.initials: MH
authors.lastname: van Beeren
authors.forename: T A
authors.initials: TA
authors.lastname: Plomp
authors.forename: H
authors.initials: H
authors.lastname: Oosting
mesh_terms: D000328:Adult; D000368:Aged; D000638:Amiodarone / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood; D002784:Cholesterol / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D013223:Statistics as Topic; D013963:Thyroid Hormones / Q000097:blood*
chemical_list: D013963:Thyroid Hormones; D002784:Cholesterol; D000638:Amiodarone